TNF and serum lipopolysaccharide activity: All existing anticytokine therapies against sepsis, including monoclonal antibody-based anticytokine therapies and our recently developed SEM18 peptide-based anti-TNF-α therapy, were designed to target a single cytokine and thus can inhibit only one cytokine when administered to treat endotoxemia and sepsis.